explore -WSS

explore

author：hotspot 2025-09-28 15:57:10 - browse：1447

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： An Ebola outbreak presents a new mystery involving children

knowledge

WSS

At Orexo, a ‘turning point’ for everything but digital health

FDA approves RSV monoclonal antibody for infants, toddlers

How dance can help nurses traumatized by Covid

Germany receives 178 compensation applications from gay servicepeople over discrimination

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

In early work, researchers turn to CRISPR to treat Alzheimer's

hotspot

explore

focus

In Memoriam: Notable people who died in 2023

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Cancer drug shortages should be causing more outrage

Judge rejects Trump's counterclaim against E. Jean Carroll

After affirmative action ruling, medical educators look to 'holistic review'

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Custom gene therapy hints at new path for rare disease treatments

In Memoriam: Notable people who died in 2023

AI can’t replace a physician’s gut feeling

focus

Google and Epic fight stronger regulation of AI in health care

Cosmetics set for new safety regulation. Why the industry is on board

Biden tests positive for Covid

Medicare to cover more brain scans for Alzheimer’s patients

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

hotspot

knowledge

entertainment

hotspot